Transforming growth factor (TGF)-b can suppress and promote breast cancer progression. How TGF-b elicits these dichotomous functions and which roles the principle intracellular effector proteins Smad2 and Smad3 have therein, is unclear. Here, we investigated the specific functions of Smad2 and Smad3 in TGF-b-induced responses in breast cancer cells in vitro and in a mouse model for breast cancer metastasis. We stably knocked down Smad2 or Smad3 expression in MDA-MB-231 breast cancer cells. The TGF-b-induced Smad3-mediated transcriptional response was mitigated and enhanced by Smad3 and Smad2 knockdown, respectively. This response was also seen for TGF-b-induced vascular endothelial growth factor (VEGF) expression. TGF-b induction of key target genes involved in bone metastasis, were found to be dependent on Smad3 but not Smad2. Strikingly, whereas knockdown of Smad3 in MDA-MB-231 resulted in prolonged latency and delayed growth of bone metastasis, Smad2 knockdown resulted in a more aggressive phenotype compared with control MDA-MB-231 cells. Consistent with differential effects of Smad knockdown on TGF-b-induced VEGF expression, these opposing effects of Smad2 versus Smad3 could be directly correlated with divergence in the regulation of tumor angiogenesis in vivo. Thus, Smad2 and Smad3 differentially affect breast cancer bone metastasis formation in vivo.
Introduction
Metastatic breast cancer is one of the leading causes of death from cancer in women. Transforming growth factor (TGF)-b is frequently overexpressed in human breast tumors and the tumor-associated stroma and its expression correlates with poor prognosis and metastasis (Ghellal et al., 2000; Sheen-Chen et al., 2001; Ivanovic et al., 2003; Desruisseau et al., 2006) . TGF-b is the prototypic member of a large family of evolutionarily conserved pleiotropic cytokines, including three TGF-b isoforms, activins and bone morphogenetic proteins (BMPs) (Moustakas and Heldin, 2007; Schmierer and Hill, 2007; Massague, 2008) . TGF-b family members have critical and specific roles during embryogenesis and later in maintaining tissue homeostasis. Perturbations in their signaling pathways have been linked to a diverse set of developmental disorders and diseases, including cancer, fibrosis and autoimmune diseases (Kirkbride and Blobe, 2003) . These factors signal through specific sets of type I and type II serine/threonine kinase receptors. TGF-b binds to the TGF-b type II receptor (TbRII), which in turn transactivates the TGF-b type I receptor, also termed activin receptor-like kinase (ALK)5. Activated ALK5 recruits and phosphorylates the receptor-regulated Smads (R-Smads) Smad2 and Smad3. These can then form heteromeric complexes with Smad4, translocate to the nucleus and control the activation or repression of target genes (ten Dijke and Hill, 2004) . Smad2 and Smad3 are also used by activin as downstream-signaling mediators (Burdette et al., 2005) , whereas BMPs use the R-Smads Smad1, 5 and 8 (Massague et al., 2005) . Smad2 and Smad3 are highly conserved proteins with 83.9% amino acid sequence identity ( Figure 1a ). The major structural difference between Smad2 and Smad3 is in the mad homology (MH) 1 domain where Smad2 has two short peptide inserts, amino acids 21-30 and 79-108 (Dennler et al., 1999) . The latter insert imposes steric constraints that prevent Smad2 from binding to DNA (Dennler et al., 1999) . Smad3 on the other hand readily binds DNA in complex with Smad4.
TGF-b has a dual role in tumorigenesis (Massague, 2008) . It inhibits growth of early carcinomas whereas in advanced stages of carcinogenesis TGF-b promotes tumor growth. TGF-b can further stimulate tumor progression and metastasis by inducing epithelial to mesenchymal transition (EMT) and invasion of epithelial cancer cells, Moustakas and Heldin, 2007) and by suppressing anti-tumor immune responses (Kirkbride and Blobe, 2003; Moustakas and Heldin, 2007) .
Furthermore, several studies have shown that TGF-b can promote tumor angiogenesis and thereby create a favorable microenvironment for rapid tumor growth and dissemination (Donovan et al., 1997; Nawshad et al., 2005) . In breast cancer bone metastasis target genes of TGF-b are essential for cell homing, establishment of micrometastatic lesions and in the self-amplifying process of tumor-induced bone resorption (Yin et al., 1999; Kingsley et al., 2007; Buijs and van der Pluijm, 2009 ).
The TGF-b-signaling pathway has been extensively studied in cancer patients and in animal models of xenografted tumors and metastasis. In human cancers diffuse phosphorylated Smad2 (P-Smad2) staining has been observed indicative of active TGF-b signaling (Xie et al., 2002; Kang et al., 2005; Bruna et al., 2007) . Disrupting TGF-b signaling in human breast cancer cells induced tumorigenesis but inhibited invasion and metastasis to lungs after tail vein injection. This was studied by ectopic overexpression of mutated R-Smads or receptors mutated at the R-Smad-binding site (McEarchern et al., 2001; Oft et al., 2002; Tian et al., 2003 Tian et al., , 2004 . Also, when using ALK5 inhibitors in vivo primary tumor growth was inhibited and the number of metastases was reduced (Ge et al., 2006; Ehata et al., 2007) . In a model of mouse breast cancer metastasis of 4T1 cells, administration of anti-TGF-b antibody to mice reduced the number of metastasis by 50-60% (Nam et al., 2008) . In the 4T1 and the MDA-MB-231 tumor models, systemic administration of a soluble TbRII protein or dominant negative TbRII overexpression, respectively, displayed anti-metastatic effects (Yin et al., 1999; Muraoka et al., 2002) . Several studies have provided evidence that Smad2 and Smad3 have different transcriptional functions and profiling studies have revealed distinct target genes for Smad2 and Smad3 (Kretschmer et al., 2003; LaGamba et al., 2005; Dzwonek et al., 2009 ). In addition, although mice deficient in Smad2 are embryonic lethal, Smad3-deficient mice are viable (Weinstein et al., 1998; Ashcroft et al., 1999; Yang et al., 1999) . These observations clearly suggest that Smad2 and Smad3 have distinct functions in vivo. In a skin cancer model in mice, homozygous deletion of Smad2 in keratinocytes triggered an EMT phenotype in tumors. This was observed by downregulation of E-cadherin expression and induction of Vimentin, a-smooth muscle actin and the E-Cadherin repressor Snail (Hoot et al., 2008) . In contrast, overexpression of activated Smad2/3 was shown to increase cell motility in a squamous skin tumorigenesis model (Oft et al., 2002) . Nevertheless, the specific functions for Smad2 and Smad3 in breast cancer are not known.
We and others previously reported that silencing Smad4 in breast cancer cells delayed the formation of bone metastasis in vivo (Kang et al., 2005; Deckers et al., 2006) . To particularly study the contribution of TGF-b signaling in metastasis and explore the exact role of either Smad2 or Smad3, we stably silenced these molecules in an osteotropic clone of the human breast cancer cell line MDA-MB-231. A mouse model of bone metastasis was used to study the differential role of the R-Smads in metastatic progression (Deckers et al., 2006; Buijs et al., 2007a) . Tumor growth and metastasis were quantified in vivo by bioluminescent imaging (BLI). Our results show that, depending on the type of R-Smad silenced the metastatic potential of the human breast cancer cells is differentially and significantly affected.
Results

Specific silencing of Smad2 or Smad3 using miR RNAi
The TGF-b signaling cascade has crucial roles in breast cancer metastasis. We previously found that silencing Smad4 in MDA-MB-231 cells inhibits bone metastasis formation in vivo (Deckers et al., 2006) . To examine direct effects of TGF-b signaling and in particular of the TGF-b R-Smads, we designed and cloned miR RNAi constructs specifically targeting either Smad2 or Smad3.
These R-Smads are highly homologous with the exception of the MH1 domain ( Figure 1a ) where Smad2 has two additional short peptide inserts compared with Smad3 (Dennler et al., 1999) . The targeting miR RNAi sequences were therefore designed to the additional peptide stretches in the MH1 domain of Smad2 and to the flanking sequences of this region in Smad3. We first examined the efficiency of knockdown of the miR RNAi constructs in a pcDNA 3.1 vector by co-transfection with FLAG-tagged Smad2 or Smad3 in COS cells. A non-targeting (N-T) miR RNAi was used as control. As seen by immunoblot analysis (Figure 1b , lanes 4 and 8) both Smad2 and Smad3 were specifically and efficiently silenced by the corresponding miR RNAi. The miR RNAi pcDNA constructs were tested on a specific TGFb-inducible Smad3/Smad4 responsive CAGA-luciferase reporter in COS and MDA-MB-231 cells. The miR RNAi targeting Smad3 significantly reduced the TGF-binduced CAGA-luc activity ( Figure 1c ). The basal level of activity was similarly reduced suggesting that knockdown of Smad3 inhibits autocrine TGF-b signaling. This effect could be rescued by overexpression of Smad3-FLAG. Smad2 miR RNAi significantly potentiated the TGF-b-induced activity (Figure 1c ), suggesting that more Smad3 is accessible at the promoter when Smad2 is eliminated. Neither of the miR RNAi constructs had an effect on the BMP-responsive reporter indicating that the miR RNAi's selectively target Smad2 or Smad3 and not BMP R-Smads or Smad4 (data not shown).
The miR RNAi constructs were sub-cloned into lentiviral vectors and MDA-MB-231-luc cells were infected. Several single cell clones stably expressing miR RNAi's were selected and characterized. As shown in Figure 1d , the stable clones showed efficient knockdown for Smad2 or Smad3. The protein levels of Smad2 in the Smad2 miR RNAi clones were 90-95% reduced. The best knockdown clones with miR RNAi for Smad3 showed a 70-80% reduction of Smad3 protein levels. No cross-targeting was observed for either construct.
Thus, Smad2 and Smad3 are potently and specifically silenced by lentiviral-delivered miR RNAi.
Binding of TGF-b to its receptor leads to transphosphorylation of R-Smads. To determine if the levels of phosphorylated Smad2 were elevated in clones silenced for Smad3 and vice versa, we stimulated the stable cell lines with TGF-b (Supplementary Figure S1) . We further confirmed that a very sufficient knockdown is obtained with the miR RNAi's because no P-Smad2 or P-Smad3 were observed in Smad2 and Smad3 silenced clones, respectively. Furthermore, we found that the level of phosphorylation of one R-Smad was unchanged when the other was silenced. This suggests that the TGF-b-induced activation of R-Smads in MDA-MB-231 cells is non-competitive. To characterize the tumorigenic potential of the cells we performed a colony formation assay in soft agar. We observed no difference in the number of colonies formed or in the size of the aggregates (data not shown).
Proliferation of miR RNAi stable clones
Silencing Smad3 affects TGF-b target genes Important TGF-b-responsive genes involved in the vicious cycle of osteolytic bone metastasis include interleukin (IL)-11, parathyroid hormone-related protein and connective tissue growth factor (CTGF) (Yin et al., 1999; van der Pluijm et al., 2001; Deckers et al., 2006; Kingsley et al., 2007) . We hypothesized that silencing either Smad2 or Smad3 would have an effect on the regulation of TGF-b target genes and perhaps give an indication of the metastatic potential of the cells. Smad2 and Smad3 in breast cancer bone metastases M Petersen et al IL-11 mRNA levels was seen after 6 h stimulation with TGF-b in N-T control and Smad2 miR RNAi cells (Figure 3a) . When Smad3 was silenced this induction was significantly inhibited in multiple clones. In addition, TGF-b-induced PAI-1 expression levels were significantly reduced in Smad3 knockdown cells compared with the control and Smad2 knockdown cells (Figure 3b ). We also examined the TGF-b-induced upregulation of CTGF (Figure 3c ). CTGF mRNA levels were significantly increased after TGF-b stimulation in the N-T control cells. In Smad2 and Smad3 miR RNAi cells both basal and TGF-b-induced CTGF mRNA levels were reduced. However, the fold induction with TGF-b stimulation was comparable with the N-T control. Parathyroid hormone-related protein mRNA levels were 5 fold induced by TGF-b in all three cell lines (Figure 3d ). To control for off-target effects of the miR RNAi's we used Smad2 and Smad3 shRNAi lentiviral constructs. This resulted in 70-80% knockdown of endogenous protein levels (Supplementary Figure S2a) . The gene expression analysis was repeated and the effect on TGF-b-induced target genes were confirmed in MDA-BO2 cells stably expressing shRNAi for Smad2 or Smad3 (Supplementary Figure S2b-f) . Thus, independent approaches for Smad2 or Smad3 knockdown gave nearly identical results indicating that effects of the miR RNAi's are on-target.
Smad2 and Smad3 differentially affect bone metastasis
Our observations in vitro suggest that both R-Smads are necessary for TGF-b-induced migration, whereas Smad3 appears to be more important in the regulation of TGF-b target genes. We evaluated the specific effect of either Smad2 or Smad3 in an experimental mouse model of bone metastasis where osteotropic MDA-MB-231-luc cells were inoculated into the left heart ventricle (Deckers et al., 2006; Buijs et al., 2007a) . This model recapitulates late stages of metastatic progression, namely, survival in the circulation, extravasation and establishment of metastases at secondary sites. Mice were injected with breast cancer cells stably silenced for Smad2, Smad3 or an N-T control. Establishment and growth of bone metastatic cells was followed in time with BLI ( Figure 4a ) (Buijs et al., 2007a) . The metastatic growth was plotted as the average total body flux of each experimental group in time (Figure 4b ). Smad2 miR cells showed a significantly more aggressive phenotype compared with both the N-T control and Smad3 miR cell lines (Pp0.001 versus Smad3 miR RNAi). In contrast, Smad3-silenced cells displayed a prolonged lag time of tumor growth in the bones (Figure 4b ). This can be more readily observed from the inset of Figure 4b , which demonstrates the tumor growth from day 21 to 35. At this stage the Smad2-silenced metastases are growing at an exponential rate, whereas the Smad3 miR RNAi cells are still in a 'lag phase' (P ¼ 0.046 Smad2 miR versus Smad3 miR RNAi). N-T control miR RNAi cells are also starting to grow exponentially at this phase. However, at the end of the experiment there was no significant difference in the total BLI emission from Smad3 miR versus N-T control miR-injected mice (Figure 4b ). No significant differences were detected in the total number of metastases per animal in each of the three groups (Figure 4c ). However, it appears that there is a tendency for more metastases at an earlier stage in the Smad2 miR RNAi group compared with the N-T and Smad3 miR RNAi groups. A rise in metastasis is observed from day 35 to 45 in the N-T and Smad3 miR RNAi groups.
Fluorescence imaging was used to visualize the spatial volume of the tumors in vivo and examine if the miR RNAi were still actively being expressed. This can be done, because the lentivirally inserted miR RNAi cocistronically express GFP. As seen in Figure 4d , showing a Smad2 miR RNAi-injected mouse, the bone metastases were highly GFP positive. Radiographies of the same animal reveal the existence of osteolytic bone lesions at the same sites. By re-establishment of cell lines from bone marrow aspirates of metastases we found that the stable cell lines were continuously silenced for Figure S3) .
Bone metastases are detected as areas of low mineral density where the bone has been extensively resorbed by tumor-induced osteoclasts ( Figure 5 ). All experimental groups displayed strong osteolytic metastases. In general, the bone metastases were located in the distal femur, proximal tibia, vertebra, mandibula and os coxae (Figure 5a, arrow heads) . When comparing radiographies of mice from different experimental groups, with similar BLI emission, we found no apparent differences in bone destruction (Figure 5a ). This observation was further substantiated by histomorphologic analysis (Figures 5a and b) . Masson-Goldner staining revealed extensive bone loss and nearly complete replacement of the bone marrow with breast cancer cells.
Smad2 and Smad3 differentially regulate angiogenesis
We observed significant differences in metastatic growth of the Smad2 and Smad3 miR RNAi cell lines in vivo. 
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This was seen already at early stages of the metastatic process where the initial growth of Smad3 miR RNAi tumors at the metastatic site was inhibited. At this phase angiogenesis is critically important for metastatic growth (Kang et al., 2003; Kingsley et al., 2007) . We therefore hypothesized that Smad2 and Smad3 could have differential effects on angiogenesis. Vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis and directly associated with worse prognosis in patients with invasive breast cancer (Heffelfinger et al., 1999) . Inhibition of VEGF signaling results in the inhibition of breast cancer metastasis (Matsui et al., 2008) . VEGF is a direct TGF-b target gene and Smad3, but not Smad2, was previously shown to mediate TGF-b-induced VEGF production (SanchezElsner et al., 2001; Kobayashi et al., 2005) . We therefore analyzed the expression of VEGF-A in the stable miR RNAi clones after 6 and 24 h TGF-b stimulation (Figure 6a ). TGF-b significantly induced VEGF expression at both time points. Interestingly, when Smad2 was silenced the basal VEGF levels were dramatically increased. In cells lacking Smad3 the TGF-b-induced VEGF expression was lost. We next examined the amount of VEGF secreted in conditioned medium from the miR RNAi clones after TGF-b stimulation (Figure 6b ). In the N-T control miR RNAi cells, TGF-b induced VEGF secretion by threefold. In Smad2 miR RNAi cells, threefold more VEGF was secreted compared with the N-T control and Smad3 miR RNAi under unstimulated conditions. This secretion could be further enhanced by TGF-b stimulation. In Smad3 miR RNAi cells TGF-b was unable to induce VEGF production. Thus, the VEGF secretion studies confirmed our transcription profiling results. To further verify if our observations in vitro would explain the differences in tumor burden in vivo, we visualized the micro-vascular network in the bone metastatic sections by CD31 (PECAM-1) immunolocalization (Kang et al., 2003; Buijs et al., 2007a) . Images of the preparations were evaluated by blinded quantification of the micro-vascular density (MVD) and computer analysis of the percentage of capillary area (Figures 6c  and d) . Significantly more vascular structures were observed in bone metastases originating from Smad2 miR RNAi cells compared with N-T and Smad3 miR RNAi cells. Furthermore, the expression of the proangiogenic factors hypoxia inducible factor-1a (HIF-1a) and placenta growth factor (PlGF) was enhanced in RNA isolated from Smad2 miR RNAi metastases compared with N-T and Smad3 miR RNAi (Supplementary Figure S4 ). Together these results show that Smad2 and Smad3 differentially regulate tumor angiogenesis thus, providing an explanation for the observed differences in tumor growth at bone metastatic sites.
Discussion
The concept that the TGF-b-signaling pathway has an important role in tumorigenesis and metastases of breast cancer is well established (Massague, 2008) in clinical and in vivo studies (Leivonen and Kahari, 2007) . Recently, we and others showed a pro-metastatic role of Smad4 in breast cancer bone metastasis of MDA-MB-231 cells (Kang et al., 2005; Deckers et al., 2006) . Owing to the nature of Smad4 as a central regulator of both TGF-b and BMP signaling (Deckers et al., 2006; Buijs et al., 2007a) we decided to further study the role of the TGF-b Smad-dependent pathway in breast cancer metastasis by specific knockdown of either Smad2 or Smad3. Smad2 or Smad3 expression was eliminated by miR RNAi in the highly aggressive breast cancer cell line MDA-MB-231 and the effect of knockdown was evaluated in several in vitro assays. Furthermore, the metastatic potential of the cells was characterized in a mouse model of bone metastasis (Kang et al., 2003) . Our in vivo model recapitulates late events in the metastatic cascade including survival in the circulation, homing to bone, extravasation in the bone and establishment of micrometastatic disease (Buijs et al., 2007b) . We show, for the first time, that Smad2 and Smad3 have distinct roles in osteotropic breast cancer. Strikingly, Smad2-silenced MDA-MB-231 cells were considerably more aggressive in vivo than cells silenced for Smad3 or a nontargeting control, despite the fact that they displayed slightly slower proliferation in vitro. In contrast, Smad3 knockdown cells showed a prolonged lag phase of tumor growth in the bone microenvironment. These observations are in line with recent findings by Hoot et al. (2008) who reported that homozygous deletion of Smad2 potentiated EMT and tumor aggressiveness in a skin cancer model. In these cells a direct upregulation of critical EMT target genes such as SNAIL and Vimentin was observed along with a reduced E-Cadherin expression in the Smad2 À/À skin tumors compared with wildtype tumors. We were unable to study the role of EMT in our model, which recapitulates later stages of tumorigenesis (Deckers et al., 2006) . Also, Smad2 heterozygous mice displayed accelerated tumor formation and progression compared with wild-type control mice (Tannehill-Gregg et al., 2004) and reduced P-Smad2 staining was correlated with a shorter overall survival in patients with stage II breast cancer (Xie et al., . Taken together, these observations support our findings regarding the pro-metastatic effects of Smad2 knockdown in breast cancer and suggest that Smad2 has a tumor suppressor role. Bone metastases originating from Smad3 knockdown cells took considerably longer to develop into overt bone lesions. Nevertheless, at the end of the experiment growth of the Smad3 miR RNAi tumors was similar to the N-T control miR RNAi tumors perhaps because of the fact that the knockdown efficiency of Smad3 is not absolute (70-80%). Alternatively, the tumor might induce alternative responses to compensate for the loss of Smad3 as suggested from our findings on HIF-1a and PlGF expression in Smad3 miR RNAi metastases (Ebos et al., 2009; Paez-Ribes et al., 2009) . The increased lag phase of bone metastatic growth of Smad3-silenced cancer cells may be explained by altered expression of TGF-b target genes that were no longer responsive to TGF-b when Smad3 was silenced, whereas Smad2 knockdown had a limited effect on these target genes.
In particular, critical genes involved in the vicious cycle of osteolytic bone metastases, including IL-11, CTFG and PAI-1 were affected. IL-11 is an important osteolytic factor secreted by the cancer cells to stimulate osteoclastic bone resorption. CTGF and PAI-1 have been reported to stimulate survival in the bone microenvironment through the induction of angiogenesis (Isogai et al., 2001; Kingsley et al., 2007) . Comparable observations were reported for MDA-MB-231 cells knocked down for Smad4 (Kang et al., 2005; Deckers et al., 2006) .
Blocking the function of endogenous Smad3 in the MCF10A-derived breast cancer cells strongly suppressed the formation of metastatic foci in lungs of mice (Tian et al., 2003 (Tian et al., , 2004 , thus supporting our Smad3 findings. In the same study, overexpression of a defective binding mutant of Smad3 enhanced malignancy of primary tumors (Tian et al., 2004) . This is in line with previous findings where modulation of TGF-b receptors had no effect or even promoted primary tumor growth and at later stages of tumorigenesis significantly reduced invasion and metastatic progression (McEarchern et al., 2001; Ge et al., 2006; Ehata et al., 2007; Nam et al., 2008) . In our hands, TGF-b-induced migration of MDA-MB-231 cells was dependent on both Smad2 and Smad3. Overexpression of a C-terminal truncated mutant of Smad3 was previously shown to have the same effect on TGF-b-induced migration of MCF10A cells (Tian et al., 2003) . Taken together these results suggest that Smad3 is critical for stimulation of tumor growth and metastasis.
Angiogenesis is critically important for metastatic growth when the tumor reaches a size that outgrows the normal blood supply (Kang et al., 2003; Buijs et al., 2007b) . We reckoned that Smad3 miR RNAi metastases grew slower in the early phase of the experiment and that this could be explained by the diminished ability to stimulate angiogenesis in the bone metastases. Indeed, significant differences in VEGF-A mRNA expression and protein secretion were observed. In the Smad3 miR RNAi cell line the TGF-b-induced upregulation of VEGF was lost, whereas in the Smad2 miR RNAi cell line both VEGF expression and secretion was significantly increased. Enhanced angiogenesis was also observed in tumor metastatic sections in Smad2 miR RNAi-inoculated animals in agreement with the notion that VEGF expression directly correlates with the degree of malignancy (Heffelfinger et al., 1999) . In line with our findings, Smad2 was found to mediate secretion of factors with anti-angiogenic properties, whereas Smad3 induced the secretion of pro-angiogenic factors by other epithelial cells (Nakagawa et al., 2004) . Furthermore, conditioned medium from Smad2 knockout fibroblasts induced proliferation of endothelial cells, whereas medium from Smad3 knockout cells had no effect (Nakagawa et al., 2004) . These findings support our observations namely that loss of Smad2 potentiates angiogenesis and loss of Smad3 inhibits tumor angiogenesis in breast cancer cells.
We show, for the first time, that Smad2 and Smad3 have distinct roles in breast cancer bone metastasis of MDA-MB-231 cells. Loss of Smad2 significantly increases the metastatic potential whereas loss of Smad3 shows a delayed growth of micro-metastases. These differences can be explained by the distinct roles of Smad2 and Smad3 in tumor-induced angiogenesis. In conclusion, our observations provide evidence that the Smad3 pathway mediates pro-metastatic activities in invasive cells and suggest that Smad2 has tumor suppressor activities. Current therapeutic strategies are aiming at antagonizing the TGF-b receptors thereby completely blocking signaling of both Smad2 and Smad3. Despite the validity of this approach our findings indicate that selective targeting of Smad3 may lead to more effective therapeutic responses in the treatment of bone metastasis.
Materials and methods
Cell culture and reagents MDA-MB-231-luc, MDA-BO2-luc, COS, HEK293 T cells were maintained as previously described (Deckers et al., 2006; Buijs et al., 2007a) . Cells were stimulated with TGF-b3 and BMP-6 at 5 and 100 ng/ml, respectively. SB431542 (Tocris bioscience, Bristol, UK) was used at 10 mM as previously reported (Petersen et al., 2008) .
Constructs and cloning
We used BLOCK-iT Pol II micro RNA interference (miR RNAi) technology (Invitrogen, Breda, The Netherlands) for transient and stable knockdown of Smad2 and Smad3 (see Supplementary Methods for details).
Animals and surgical procedures
Four-to five-week-old female BAlb-c nu/nu mice (Charles River, Maastricht, The Netherlands) were anaesthetized with isouorane 0.8 l/min and 1 Â 10 5 freshly harvested MDA-MB-231-luc miR RNAi cells in 100 ml PBS were inoculated into the left heart ventricle (n ¼ 10 per group) (Deckers et al., 2006; Buijs et al., 2007a) . Injections were given with 27G syringes. All animal experiments were approved and carried out
